Ross Law, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/rosslaw/ Hard data and deep insights on clinical trials strategy & operations Fri, 08 Nov 2024 07:58:54 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png Ross Law, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/rosslaw/ 32 32 Customer-centricity takes spotlight during clinical transformation https://www.clinicaltrialsarena.com/news/customer-centricity-takes-the-spotlight-during-clinical-transformation/ Thu, 07 Nov 2024 12:38:39 +0000 https://www.clinicaltrialsarena.com/news/customer-centricity-takes-the-spotlight-during-clinical-transformation/ Alcon decided to take a platform-based approach to support its clinical transformation efforts when parent company Novartis decided to spin it out as an independent organisation in 2019.

The post Customer-centricity takes spotlight during clinical transformation appeared first on Clinical Trials Arena.

]]> The post Customer-centricity takes spotlight during clinical transformation appeared first on Clinical Trials Arena.

]]> Ondine accelerates pivotal antimicrobial trial after $11m financing https://www.clinicaltrialsarena.com/news/ondine-antimicrobrial-pivotal-trial-initiation/ Tue, 05 Nov 2024 10:12:27 +0000 https://www.clinicaltrialsarena.com/news/ondine-antimicrobrial-pivotal-trial-initiation/ Ondine’s Phase III trial will investigate its Steriwave system for nasal photodisinfection before surgery.

The post Ondine accelerates pivotal antimicrobial trial after $11m financing appeared first on Clinical Trials Arena.

]]> The post Ondine accelerates pivotal antimicrobial trial after $11m financing appeared first on Clinical Trials Arena.

]]> Alloplex’s cancer immunotherapy shows promise in Phase I trial https://www.clinicaltrialsarena.com/news/alloplex-cancer-immunotherapy-shows-promise-in-phase-i-trial/ Thu, 31 Oct 2024 10:20:31 +0000 https://www.clinicaltrialsarena.com/news/alloplex-cancer-immunotherapy-shows-promise-in-phase-i-trial/ Alloplex Biotherapeutics’ autologous SUPLEXA cell immunotherapy for cancer has demonstrated promise in a first-in-human study.

The post Alloplex’s cancer immunotherapy shows promise in Phase I trial appeared first on Clinical Trials Arena.

]]> The post Alloplex’s cancer immunotherapy shows promise in Phase I trial appeared first on Clinical Trials Arena.

]]> First participants dosed in trial of long-acting malaria preventative https://www.clinicaltrialsarena.com/news/first-participants-dosed-in-trial-of-long-acting-malaria-preventative/ Tue, 29 Oct 2024 14:06:40 +0000 https://www.clinicaltrialsarena.com/news/first-participants-dosed-in-trial-of-long-acting-malaria-preventative/ Medicines for Malaria Venture (MMV) and Quotient Sciences have dosed the first participants in a trial of MMV371, a long-acting injectable (LAI) for the prevention of malaria.

The post First participants dosed in trial of long-acting malaria preventative appeared first on Clinical Trials Arena.

]]> The post First participants dosed in trial of long-acting malaria preventative appeared first on Clinical Trials Arena.

]]> NIH launches precision medicine trial for myeloid cancers https://www.clinicaltrialsarena.com/news/nih-launches-precision-medicine-trial-for-myeloid-cancers/ Thu, 24 Oct 2024 10:38:00 +0000 https://www.clinicaltrialsarena.com/news/nih-launches-precision-medicine-trial-for-myeloid-cancers/ The US National Institutes of Health (NIH) has launched a precision medicine trial that aims to match patients with myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) to treatments based on the genetic profile of their cancer.

The post NIH launches precision medicine trial for myeloid cancers appeared first on Clinical Trials Arena.

]]> The post NIH launches precision medicine trial for myeloid cancers appeared first on Clinical Trials Arena.

]]> Kezar Life Sciences discontinues lupus nephritis programme after fatalities https://www.clinicaltrialsarena.com/news/kezar-life-sciences-discontinues-lupus-nephritis-programme-after-fatalities/ Fri, 18 Oct 2024 14:02:13 +0000 https://www.clinicaltrialsarena.com/news/kezar-life-sciences-discontinues-lupus-nephritis-programme-after-fatalities/ Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death of four patients.

The post Kezar Life Sciences discontinues lupus nephritis programme after fatalities appeared first on Clinical Trials Arena.

]]> The post Kezar Life Sciences discontinues lupus nephritis programme after fatalities appeared first on Clinical Trials Arena.

]]> NovoCure scoops FDA approval on wearable for metastatic cancer treatment https://www.clinicaltrialsarena.com/news/novocure-scoops-fda-approval-on-wearable-for-metastatic-cancer-treatment/ Thu, 17 Oct 2024 11:00:19 +0000 https://www.clinicaltrialsarena.com/uncategorized/novocure-scoops-fda-approval-on-wearable-for-metastatic-cancer-treatment/ NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval from the US FDA.

The post NovoCure scoops FDA approval on wearable for metastatic cancer treatment appeared first on Clinical Trials Arena.

]]> The post NovoCure scoops FDA approval on wearable for metastatic cancer treatment appeared first on Clinical Trials Arena.

]]> MHRA expects new UK clinical trial regulation implementation by January 2026 https://www.clinicaltrialsarena.com/news/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026/ Wed, 16 Oct 2024 11:29:21 +0000 https://www.clinicaltrialsarena.com/news/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026/ The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) expects the new UK clinical trial regulation to be implemented by January 2026.

The post MHRA expects new UK clinical trial regulation implementation by January 2026 appeared first on Clinical Trials Arena.

]]> The post MHRA expects new UK clinical trial regulation implementation by January 2026 appeared first on Clinical Trials Arena.

]]> Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib study https://www.clinicaltrialsarena.com/news/vanqua-parkinson-drug-shows-promise-as-company-initiates-phase-ib-study/ Thu, 10 Oct 2024 11:11:06 +0000 https://www.clinicaltrialsarena.com/news/vanqua-parkinson-drug-shows-promise-as-company-initiates-phase-ib-study/ Chicago-based Vanqua Bio’s Parkinson’s disease drug has shown proof-of-concept in a first-in-human study, with the company to dose Parkinson’s disease patients soon.

The post Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib study appeared first on Clinical Trials Arena.

]]> The post Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib study appeared first on Clinical Trials Arena.

]]> FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study https://www.clinicaltrialsarena.com/news/fda-gives-adcendo-green-light-to-trial-adc-in-phase-i-sarcoma-study/ Tue, 08 Oct 2024 10:46:56 +0000 https://www.clinicaltrialsarena.com/news/fda-gives-adcendo-green-light-to-trial-adc-in-phase-i-sarcoma-study/ Adcendo’s antibody-drug conjugate (ADC) candidate will enter a Phase I/II study after receiving Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA).

The post FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study appeared first on Clinical Trials Arena.

]]> The post FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study appeared first on Clinical Trials Arena.

]]>